# AstraZeneca plc -6.2% potential downside indicated by Deutsche

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-6-2-potential-downside-indicated-by-deutsche/4121146479
- Published: 2024-03-07T13:49:08+00:00
- Author: Charlotte Edwards

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**
with ticker ([LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
now has a potential downside of -6.2% according to Deutsche.
Deutsche set a target
price of 9,500 GBX for the company, which when compared to the AstraZeneca plc share
price of 10,132 GBX at opening today (07/03/2024) indicates a potential downside
of -6.2%. Trading has ranged between 9,461 (52 week low) and 12,828 (52 week high)
with an average of 2,487,383 shares exchanging hands daily. The market capitalisation
at the time of writing is £157,495,772,700.AstraZeneca PLC is a science-led biopharmaceutical
company. The Company focuses on the discovery, development, and commercialization
of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including
cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline
forms a portfolio of investigational therapies in various stages of clinical development
and includes the Alexion Rare Disease portfolio comprising approximately 178 projects.
Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence,
Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include
Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include
Farxiga, Lokelma, Crestor, Breztri and others. It is also focused on discovering,
developing, and manufacturing of T-cell receptor therapies. It also offers investigational
vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human
metapneumovirus.

Share on:
